🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Paul Tudor Jones’s SYRE Holdings & Trades

First Buy
Q3 2024
Duration Held
3 Quarters
Largest Add
Q3 2024
+31,138 Shares
Current Position
10,127 Shares
$331,761 Value

Paul Tudor Jones's SYRE Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 10,127 shares of Spyre Therapeutics, Inc. (SYRE) worth $331,761, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 3 quarters.

Based on 13F filings, Paul Tudor Jones has maintained this position in SYRE for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 10,127 shares. Largest reduction occurred in Q4 2024, reducing 31,138 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Spyre Therapeutics (SYRE) Holding Value Over Time

Track share changes against reported price movement

Quarterly Spyre Therapeutics (SYRE) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +10,127 New Buy 10,127 $32.76
Q4 2024 -31,138 Sold Out 0 $0.00
Q3 2024 +31,138 New Buy 31,138 $29.41

Paul Tudor Jones's Spyre Therapeutics Investment FAQs

Paul Tudor Jones first purchased Spyre Therapeutics, Inc. (SYRE) in Q3 2024, acquiring 31,138 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Spyre Therapeutics, Inc. (SYRE) for 3 quarters since Q3 2024.

Paul Tudor Jones's largest addition to Spyre Therapeutics, Inc. (SYRE) was in Q3 2024, adding 31,138 shares worth $915,769.

According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 10,127 shares of Spyre Therapeutics, Inc. (SYRE), valued at approximately $331,761.

As of the Q4 2025 filing, Spyre Therapeutics, Inc. (SYRE) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Spyre Therapeutics, Inc. (SYRE) was 31,138 shares, as reported at the end of Q3 2024.